The malfunction in UPS activity in multiple diseases has become the focus of various drug discovery efforts aimed at developing small molecule inhibitors. Despite the successes with the proteasome inhibitors, developing modulators of other enzymes in the UPS has, however proven challenging due to the complexity of research reagents and strategies. UbiQ offers innovative reagents and an experienced team to help you to overcome these challenges.
Ubiquitylation requires the consecutive action of E1, E2, and E3 enzymes in defined combinations to provide specificity for the protein target and to control the nature of the Ub chain topology. Deubiquitinating enzymes (DUBs) can reverse this process by cleaving the peptide or isopeptide bond between ubiquitin and its substrate protein.
“UbiQ offers innovative reagents and an experienced team to help you to overcome these challenges”
Both ubiquitinating and deubiquitinating enzymes are considered promising drug targets. Human ubiquitin (-like) systems consist of about a dozen E1 enzymes, several dozens of E2 enzymes, hundreds of E3 ligases and about a hundred DUBs.
accelerate drug discovery
Access to well defined ubiquitinated peptides and conjugates, has proven to be of paramount importance for research in the ubiquitin proteasome system (UPS). Since 2010, UbiQ’s ubiquitin-related reagents have enabled leading pharmaceutical companies to start and make rapid progress in all three phases of early stage drug discovery. Ranging from target identification, to lead discovery, and lead on target validation.
Download our factsheeton drug discovery in the UPS or download our factsheeton our Triple E platform for drug discovery. Discover how UbiQ can assist your early drug discovery in the UPS:
